Indivior (NASDAQ:INDV) Stock Dropped to “Buy” by Wall Street Zen

Wall Street Zen cut shares of Indivior (NASDAQ:INDV) from a strong-buy rating to a buy rating in a research note published on Saturday morning,Wall Street Zen reports.

A number of other analysts also recently issued reports on the company. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Barclays increased their price objective on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday. Craig Hallum reissued a “buy” rating and set a $53.00 target price on shares of Indivior in a research report on Tuesday, August 4th. Finally, Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $46.40.

Indivior Stock Up 0.3%

Shares of Indivior stock opened at $35.37 on Friday. Indivior has a 52-week low of $27.68 and a 52-week high of $42.81. The company has a 50 day moving average of $35.20 and a 200 day moving average of $35.62. The company has a market capitalization of $4.17 billion, a P/E ratio of 9.88 and a beta of 0.87.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, October 29th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.06 by $0.26. The company had revenue of $356.00 million for the quarter, compared to the consensus estimate of $329.35 million. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. As a group, research analysts anticipate that Indivior will post 3.66 earnings per share for the current fiscal year.

Indivior Announces Dividend

The firm also recently announced a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be issued a $8.13 dividend.

Insider Buying and Selling at Indivior

In other news, CAO Woodrow D. Anderson acquired 1,500 shares of the business’s stock in a transaction on Thursday, August 27th. The stock was bought at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the transaction, the chief accounting officer owned 27,638 shares in the company, valued at $986,400.22. This represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

A number of institutional investors and hedge funds have recently modified their holdings of INDV. Rockefeller Capital Management L.P. grew its position in shares of Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after purchasing an additional 1,076 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Indivior in the second quarter worth $63,000. GAMMA Investing LLC acquired a new position in shares of Indivior in the second quarter worth $66,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Indivior by 11.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,533 shares of the company’s stock valued at $788,000 after acquiring an additional 2,129 shares in the last quarter. Finally, Vise Technologies Inc. lifted its position in shares of Indivior by 33.0% in the third quarter. Vise Technologies Inc. now owns 9,298 shares of the company’s stock valued at $333,000 after acquiring an additional 2,306 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior PLC (NASDAQ:INDV) is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company’s principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.